Zarama M, Raij L
Department of Medicine, Veterans Affairs Medical Center, Minneapolis, MN 55417.
Am J Kidney Dis. 1993 May;21(5 Suppl 2):100-7. doi: 10.1016/0272-6386(93)70101-4.
Systemic cardiovascular diseases are the most important cause of morbidity and mortality among patients with chronic renal failure. Hypertension, lipid-profile abnormalities, glucose intolerance, and left ventricular hypertrophy are found in most patients with chronic renal failure and are responsible for the increased incidence of atherosclerosis. Hypertension is the risk factor most susceptible to treatment, but consideration must be given in selecting an antihypertensive agent not only to its effect on blood pressure but to its effects on the other risk factors. Improper selection could impair the long-term benefit of good blood pressure control by increasing the severity of the other cardiovascular risk factors and eventually worsening the prognosis of the chronic renal failure. The remaining renal function in patients not yet in end-stage renal failure deserves special consideration; an adequate antihypertensive regimen could potentially delay the need for dialysis.
全身性心血管疾病是慢性肾衰竭患者发病和死亡的最重要原因。大多数慢性肾衰竭患者存在高血压、血脂异常、糖耐量异常和左心室肥厚,这些因素导致动脉粥样硬化发病率增加。高血压是最易受治疗影响的危险因素,但在选择抗高血压药物时,不仅要考虑其对血压的影响,还要考虑其对其他危险因素的影响。选择不当可能会因加重其他心血管危险因素的严重程度而损害良好血压控制的长期益处,并最终恶化慢性肾衰竭的预后。尚未进入终末期肾衰竭的患者的残余肾功能值得特别关注;适当的抗高血压治疗方案可能会潜在地延迟透析需求。